Publication AWA

At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published review analyses for the evaluation of reimbursement applications:

• Mibrex (rivaroxaban) for the prevention of thrombotic events in adults with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are at high risk of ischemic events
• Bellix (bilastinum) for the symptomatic treatment of allergic rhinitis and conjunctivitis (seasonal and perennial) and urticaria

We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.